Genetic causes of high and low serum HDL-cholesterol

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2032-2057

  Weissglas Volkov, Daphna ^a   Pajukanta, Päivi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary artery disease; Genetic determinant; Genome wide association studies; High density lipoprotein cholesterol; Hypoalphalipoproteinemia; Lipid; Lipoprotein; Polymorphism

Indexed keywords

ABC TRANSPORTER; ACYL COENZYME A DESATURASE 1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE INTERACTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; HAPLOTYPE MAP; HERITABILITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIFESTYLE; LIPID ANALYSIS; MOLECULAR GENETICS; MONOGENIC DISORDER; MULTIFACTORIAL INHERITANCE; PATHOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUANTITATIVE TRAIT LOCUS MAPPING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TANGIER DISEASE; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; GENETIC DISORDER; GENETICS; HEREDITY; PHENOTYPE;

ANIMALS; CHOLESTEROL, HDL; GENETIC DISEASES, INBORN; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HUMANS; LIFE STYLE; MULTIFACTORIAL INHERITANCE; PHENOTYPE;

EID: 77956812723     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R004739     Document Type: Review

References (240)

1. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707-714.
2. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497.
3. The Emerging Risk Factors Collaboration. 2009. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302: 1993-2000.
4. Sharrett, A. R., C. M. Ballantyne, S. A. Coady, G. Heiss, P. D. Sorlie, D. Catellier, and W. Patsch. 2001. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 104: 1108-1113.
5. Lloyd-Jones, D., R. Adams, M. Carnethon, G. De Simone, T. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, et al. 2009. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119: 480-486.
6. Chapman, M. J., G. Assmann, J. Fruchart, J. Shepherd, and C. Sirtori. 2004. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin. 20: 1253-1268.
7. Kareinen, A., L. Viitanen, P. Halonen, S. Lehto, and M. Laakso. 2001. Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 21: 1346-1352.
8. Rye, K. A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 ( Suppl. ): S195-S200.
9. Barter, P., J. Kastelein, A. Nunn, and R. Hobbs. 2003. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 168: 195-211.
10. Florentin, M., E. N. Liberopoulos, A. S. Wierzbicki, and D. P. Mikhailidis. 2008. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 23: 370-378.
11. de Silva, H. V., W. D. Stuart, C. R. Duvic, J. R. Wetterau, M. J. Ray, D. G. Ferguson, H. W. Albers, W. R. Smith, and J. A. Harmony. 1990. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265: 13240-13247.
12. Duchateau, P. N., C. R. Pullinger, R. E. Orellana, S. T. Kunitake, J. Naya-Vigne, P. M. O'Connor, M. J. Malloy, and J. P. Kane. 1997. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J. Biol. Chem. 272: 25576-25582.
13. Christoffersen, C., L. B. Nielsen, O. Axler, A. Andersson, A. H. Johnsen, and B. Dahlbäck. 2006. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J. Lipid Res. 47: 1833-1843.
14. Rader, D. J. 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116: 3090-3100.
15. Sviridov, D., and P. J. Nestel. 2007. Genetic factors affecting HDL levels, structure, metabolism and function. Curr. Opin. Lipidol. 18: 157-163.
16. Brunham, L. R., R. R. Singaraja, and M. R. Hayden. 2006. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu. Rev. Nutr. 26: 105-129.
17. Kuivenhoven, J. A., H. Pritchard, J. Hill, J. Frohlich, G. Assmann, and J. Kastelein. 1997. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38: 191-205.
18. Ng, D. S. 2004. Insight into the role of LCAT from mouse models. Rev. Endocr. Metab. Disord. 5: 311-318.
19. Rye, K. A., M. A. Clay, and P. J. Barter. 1999. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 145: 227-238.
20. Klos, K. L. E., and I. J. Kullo. 2007. Genetic determinants of HDL: monogenic disorders and contributions to variation. Curr. Opin. Cardiol. 22: 344-351.
21. Qasim, A., and D. J. Rader. 2006. Human genetics of variation in high-density lipoprotein cholesterol. Curr. Atheroscler. Rep. 8: 198-205.
22. Trigatti, B. L., M. Krieger, and A. Rigotti. 2003. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 1732-1738.
23. Link, J. J., A. Rohatgi, and J. A. de Lemos. 2007. HDL cholesterol: physiology, pathophysiology, and management. Curr. Probl. Cardiol. 32: 268-314.
24. Jaye, M., K. J. Lynch, J. Krawiec, D. Marchadier, C. Maugeais, K. Doan, V. South, D. Amin, M. Perrone, and D. J. Rader. 1999. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21: 424-428.
25. Lusis, A. J., R. Mar, and P. Pajukanta. 2004. Genetics of atherosclerosis. Annu. Rev. Genomics Hum. Genet. 5: 189-218.
26. de Backer, G., D. de Bacquer, and M. Kornitzer. 1998. Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis. 137 ( Suppl. ): S1-S6.
27. Singh, I. M., M. H. Shishehbor, and B. J. Ansell. 2007. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 298: 786-798.
28. Ginsberg, H. N. 2000. Nonpharmacologic management of low levels of high-density lipoprotein cholesterol. Am. J. Cardiol. 86: 41L-45L.
29. Schaefer, E. J., J. J. Genest, J. M. Ordovas, D. N. Salem, and P. W. Wilson. 1994. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis. 108 ( Suppl. ): S41-S54.
30. Genest, J., J. M. Bard, J. C. Fruchart, J. M. Ordovas, and E. J. Schaefer. 1993. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler. Thromb. 13: 1728-1737.
31. Kiss, R. S., N. Kavaslar, K. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel. 2007. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler. Thromb. Vasc. Biol. 27: 1139-1145.
32. Brooks-Wilson, A., M. Marcil, S. M. Clee, L. H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. Molhuizen, et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22: 336-345. (Pubitemid 29369523)
33. Marcil, M., A. Brooks-Wilson, S. M. Clee, K. Roomp, L. H. Zhang, L. Yu, J. A. Collins, M. van Dam, H. O. Molhuizen, O. Loubster, et al. 1999. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354: 1341-1346. (Pubitemid 29481630)
34. Kral, B. G., and D. M. Becker. 2007. Familial occurrence of abnormalities of high-density lipoprotein cholesterol. J. Clin. Lipidol. 1: 31-40.
35. Majeed, F., and M. Miller. 2008. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr. Opin. Endocrinol. Diabetes Obes. 15: 175-181.
36. Miller, M., and M. Zhan. 2004. Genetic determinants of low high-density lipoprotein cholesterol. Curr. Opin. Cardiol. 19: 380-384.
37. Yamashita, S., T. Maruyama, K. Hirano, N. Sakai, N. Nakajima, and Y. Matsuzawa. 2000. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis. 152: 271-285.
38. Ishigami, M., S. Yamashita, N. Sakai, T. Arai, I. K. Hirano, H. Hiraoka, K. Kameda-Takemura, and Y. Matsuzawa. 1994. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. 116: 257-262.
39. Tall, A. R. 2009. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am. J. Cardiol. 104: 39E-45E.
40. Marcil, M., R. Bissonnette, J. Vincent, L. Krimbou, and J. Genest. 2003. Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency. Circulation. 107: 1366-1371.
41. Santos, R. D., B. F. Asztalos, L. R. Martinez, M. H. Miname, E. Polisecki, and E. J. Schaefer. 2008. Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. J. Clin. Lipidol. 2: 237-247.
42. von Eckardstein, A. 2006. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis. 186: 231-239.
43. Yokota, H., Y. Hashimoto, S. Okubo, M. Yumoto, F. Mashige, M. Kawamura, K. Kotani, Y. Usuki, S. Shimada, K. Kitamura, et al. 2002. Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD. Atherosclerosis. 162: 399-407.
44. Hovingh, G. K., E. de Groot, W. van der Steeg, S. M. Boekholdt, B. A. Hutten, J. A. Kuivenhoven, and J. J. P. Kastelein. 2005. Inherited disorders of HDL metabolism and atherosclerosis. Curr. Opin. Lipidol. 16: 139-145.
45. Ikewaki, K., A. Matsunaga, H. Han, H. Watanabe, A. Endo, J. Tohyama, M. Kuno, J. Mogi, K. Sugimoto, N. Tada, et al. 2004. A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis. 172: 39-45.
46. Pisciotta, L., R. Miccoli, A. Cantafora, L. Calabresi, P. Tarugi, P. Alessandrini, G. Bittolo Bon, G. Franceschini, C. Cortese, S. Calandra, et al. 2003. Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. Atherosclerosis. 167: 335-345.
47. Santos, R. D., E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang, R. A. Hegele, L. R. C. Martinez, M. H. Miname, C. E. Rochitte, P. L. Da Luz, et al. 2008. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J. Lipid Res. 49: 349-357.
48. Ordovas, J. M., E. Schaefer, D. Salem, R. Ward, C. Glueck, C. Vergani, P. Wilson, and S. Karathanasis. 1986. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N. Engl. J. Med. 314: 671-677.
49. Yamakawa-Kobayashi, K., H. Yanagi, H. Fukayama, C. Hirano, Y. Shimakura, N. Yamamoto, T. Arinami, S. Tsuchiya, and H. Hamaguchi. 1999. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Hum. Mol. Genet. 8: 331-336.
50. Pagani, F., A. Sidoli, G. A. Giudici, L. Barenghi, C. Vergani, and F. E. Baralle. 1990. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J. Lipid Res. 31: 1371-1377.
51. Jeenah, M., A. Kessling, N. Miller, and S. Humphries. 1990. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol. Biol. Med. 7: 233-241.
52. Rader, D. J., J. R. Schaefer, P. Lohse, K. Ikewaki, F. Thomas, W. A. Harris, L. A. Zech, C. A. Dujovne, and H. B. Brewer. 1993. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism. 42: 1429-1434.
53. Bodzioch, M., E. Orsó, J. Klucken, T. Langmann, A. Böttcher, W. Diederich, W. Drobnik, S. Barlage, C. Büchler, M. Porsch- Ozcürümez, et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22: 347-351.
54. Rust, S., M. Rosier, H. Funke, J. Real, Z. Amoura, J. C. Piette, J. F. Deleuze, H. B. Brewer, N. Duverger, P. Denèfle, et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22: 352-355.
55. Cai, Z., P. Blumbergs, K. Cash, P. Rice, J. Manavis, J. Swift, M. Ghabriel, and P. Thompson. 2006. Paranodal pathology in Tangier disease with remitting-relapsing multifocal neuropathy. J. Clin. Neurosci. 13: 492-497.
56. Singaraja, R. R., M. Van Eck, N. Bissada, F. Zimetti, H. L. Collins, R. B. Hildebrand, A. Hayden, L. R. Brunham, M. H. Kang, J. Fruchart, et al. 2006. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 114: 1301-1309.
57. Singaraja, R. R., L. R. Brunham, H. Visscher, J. J. P. Kastelein, and M. R. Hayden. 2003. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler. Thromb. Vasc. Biol. 23: 1322-1332.
58. Probst, M. C. O., H. Thumann, C. Aslanidis, T. Langmann, C. Buechler, W. Patsch, F. E. Baralle, G. M. Dallinga-Thie, J. Geisel, C. Keller, et al. 2004. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis. 175: 269-279.
59. Oram, J. F., and A. M. Vaughan. 2006. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99: 1031-1043.
60. Serfaty-Lacrosniere, C., F. Civeira, A. Lanzberg, P. Isaia, J. Berg, E. D. Janus, M. P. Smith, P. H. Pritchard, J. Frohlich, and R. S. Lees. 1994. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 107: 85-98.
61. Ho Hong, S., J. Rhyne, K. Zeller, and M. Miller. 2002. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim. Biophys. Acta. 1587: 60-64.
62. Jonas, A. 2000. Lecithin cholesterol acyltransferase. Biochim. Biophy.s Acta. 1529: 245-256.
63. Peelman, F., J. L. Verschelde, B. Vanloo, C. Ampe, C. Labeur, J. Tavernier, J. Vandekerckhove, and M. Rosseneu. 1999. Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity. J. Lipid Res. 40: 59-69.
64. Lambert, G., N. Sakai, B. L. Vaisman, E. B. Neufeld, B. Marteyn, C. Chan, B. Paigen, E. Lupia, A. Thomas, L. J. Striker, et al. 2001. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J. Biol. Chem. 276: 15090-15098.
65. Rahalkar, A. R., F. Giffen, B. Har, J. Ho, K. M. Morrison, J. Hill, J. Wang, R. A. Hegele, and T. Joy. 2009. Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can. J. Physiol. Pharmacol. 87: 151-160.
66. Talmud, P. J. 2001. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr. Atheroscler. Rep. 3: 191-199.
67. Goldberg, I. J. 1996. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37: 693-707.
68. Brites, F., J. Verona, K. Fernández, F. Henriksen, J. Fruchart, M. Cesar, G. Castro, and R. Wikinski. 2004. HDL metabolic activities in a boy with lipoprotein lipase deficiency and his family. Eur. J. Clin. Invest. 34: 467-474.
69. Inazu, A., M. L. Brown, C. B. Hesler, L. B. Agellon, J. Koizumi, K. Takata, Y. Maruhama, H. Mabuchi, and A. R. Tall. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323: 1234-1238.
70. Maruyama, T., N. Sakai, M. Ishigami, K. Hirano, T. Arai, S. Okada, E. Okuda, A. Ohya, N. Nakajima, K. Kadowaki, et al. 2003. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis. 166: 177-185.
71. van der Steeg, W. A., G. K. Hovingh, A. H. E. M. Klerkx, B. A. Hutten, I. C. Nootenboom, J. H. M. Levels, A. van Tol, G. M. Dallinga-Thie, A. H. Zwinderman, J. J. P. Kastelein, et al. 2007. Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J. Lipid Res. 48: 674-682.
72. Inazu, A., X. C. Jiang, T. Haraki, K. Yagi, N. Kamon, J. Koizumi, H. Mabuchi, R. Takeda, K. Takata, and Y. Moriyama. 1994. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J. Clin. Invest. 94: 1872-1882.
73. Boekholdt, S. M., and J. F. Thompson. 2003. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J. Lipid Res. 44: 1080-1093.
74. Curb, J. D., R. D. Abbott, B. L. Rodriguez, K. Masaki, R. Chen, D. S. Sharp, and A. R. Tall. 2004. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45: 948-953.
75. Moriyama, Y., T. Okamura, A. Inazu, M. Doi, H. Iso, Y. Mouri, Y. Ishikawa, H. Suzuki, M. Iida, J. Koizumi, et al. 1998. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27: 659-667.
76. Hirano, K., S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T. Arai, K. Yanagi, S. Takami, and M. Menju. 1995. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15: 1849-1856.
77. de Grooth, G. J., A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven. 2004. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45: 1967-1974.
78. Ruel, I. L., P. Couture, C. Gagne, Y. Deshaies, J. Simard, R. A. Hegele, and B. Lamarche. 2003. Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. J. Lipid Res. 44: 1508-1514.
79. Connelly, P. W., and R. A. Hegele. 1998. Hepatic lipase deficiency. Crit. Rev. Clin. Lab. Sci. 35: 547-572.
80. Hegele, R. A., J. A. Little, C. Vezina, G. Maguire, L. Tu, T. Wolever, D. Jenkins, and P. Connelly. 1993. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb. 13: 720-728.
81. Jansen, H., A. J. M. Verhoeven, and E. J. G. Sijbrands. 2002. Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res. 43: 1352-1362.
82. Brown, R. J., and D. J. Rader. 2007. Lipases as modulators of atherosclerosis in murine models. Curr. Drug Targets. 8: 1307-1319.
83. Deeb, S. S., A. Zambon, M. C. Carr, A. F. Ayyobi, and J. D. Brunzell. 2003. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J. Lipid Res. 44: 1279-1286.
84. Hirschhorn, J. N., and M. J. Daly. 2005. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6: 95-108.
85. Shoulders, C., E. Jones, and R. Naoumova. 2004. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum. Mol. Genet. 13: R149-160.
86. Rust, S., M. Walter, H. Funke, A. von Eckardstein, P. Cullen, H. Y. Kroes, R. Hordijk, J. Geisel, J. Kastelein, H. O. Molhuizen, et al. 1998. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat. Genet. 20: 96-98.
87. Ordovas, J. M. 2002. HDL genetics: candidate genes, genome wide scans and gene-environment interactions. Cardiovasc. Drugs Ther. 16: 273-281.
88. Wang, X., and B. Paigen. 2005. Genetics of variation in HDL cholesterol in humans and mice. Circ. Res. 96: 27-42.
89. Bosse, Y., Y. C. Chagnon, J. Despres, T. Rice, D. C. Rao, C. Bouchard, L. Perusse, and M. Vohl. 2004. Compendium of genome-wide scans of lipid-related phenotypes: adding a new genome-wide search of apolipoprotein levels. J. Lipid Res. 45: 2174-2184.
90. Dastani, Z., J. C. Engert, J. Genest, and M. Marcil. 2006. Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335.
91. Shearman, A. M., J. Ordovas, L. Cupples, E. Schaefer, M. Harmon, Y. Shao, J. Keen, A. DeStefano, O. Joost, P. Wilson, et al. 2000. Evidence for a gene influencing the TG/HDL-C ratio on chromosome 7q32.3-qter: a genome-wide scan in the Framingham study. Hum. Mol. Genet. 9: 1315-1320.
92. Pajukanta, P., H. Allayee, K. Krass, A. Kuraishy, A. Soro, H. Lilja, R. Mar, M. Taskinen, I. Nuotio, M. Laakso, et al. 2003. Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am. J. Hum. Genet. 72: 903-917.
93. Mahaney, M. C., L. Almasy, D. Rainwater, J. VandeBerg, S. Cole, J. Hixson, J. Blangero, and J. MacCluer. 2003. A quantitative trait locus on chromosome 16q influences variation in plasma HDL-C levels in Mexican Americans. Arterioscler. Thromb. Vasc. Biol. 23: 339-345.
94. Dastani, Z., L. Quiogue, C. Plaisier, J. Engert, M. Marcil, J. Genest, and P. Pajukanta. 2006. Evidence for a gene influencing high-density lipoprotein cholesterol on chromosome 4q31.21. Arterioscler. Thromb. Vasc. Biol. 26: 392-397.
95. Wang, W. Y. S., B. J. Barratt, D. G. Clayton, and J. A. Todd. 2005. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet. 6: 109-118.
96. Altshuler, D., L. Brooks, A. Chakravarti, F. Collins, M. Daly, and P. Donnelly. 2005. A haplotype map of the human genome. Nature. 437: 1299-1320.
97. Boes, E., S. Coassin, B. Kollerits, I. M. Heid, and F. Kronenberg. 2009. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp. Gerontol. 44: 136-160.
98. Pollex, R. L., and R. A. Hegele. 2007. Genetic determinants of plasma lipoproteins. Nat. Clin. Pract. Cardiovasc. Med. 4: 600-609.
99. Boekholdt, S. M., F. Sacks, J. Jukema, J. Shepherd, D. Freeman, A. McMahon, F. Cambien, V. Nicaud, G. de Grooth, P. Talmud, et al. 2005. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13 677 subjects. Circulation. 111: 278-287.
100. Isaacs, A., F. A. Sayed-Tabatabaei, O. T. Njajou, J. C. M. Witteman, and C. M. van Duijn. 2004. The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J. Clin. Endocrinol. Metab. 89: 3858-3863.
101. Wittrup, H. H., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 1999. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 99: 2901-2907.
102. Hutter, C. M., M. A. Austin, F. M. Farin, H. Viernes, K. L. Edwards, D. L. Leonetti, M. J. McNeely, and W. Y. Fujimoto. 2006. Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. Atherosclerosis. 185: 78-86.
103. Ma, K., M. Cilingiroglu, J. D. Otvos, C. M. Ballantyne, A. J. Marian, and L. Chan. 2003. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl. Acad. Sci. USA. 100: 2748-2753.
104. Tang, N. P., L. Wang, L. Yang, B. Zhou, H. Gu, Q. Sun, R. Cong, H. Zhu, and B. Wang. 2008. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. J. Lipid Res. 49: 369-375.
105. Paré, G., D. Serre, D. Brisson, S. S. Anand, A. Montpetit, G. Tremblay, J. C. Engert, T. J. Hudson, and D. Gaudet. 2007. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am. J. Hum. Genet. 80: 673-682.
106. Boekholdt, S. M., O. W. Souverein, M. W. T. Tanck, G. K. Hovingh, J. A. Kuivenhoven, R. I. G. Peters, H. Jansen, P. M. H. Schiffers, E. E. van der Wall, P. A. Doevendans, et al. 2006. Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clin. Genet. 69: 263-270.
107. Miller, M., J. Rhyne, S. Hamlette, J. Birnbaum, and A. Rodriguez. 2003. Genetics of HDL regulation in humans. Curr. Opin. Lipidol. 14: 273-279.
108. Devlin, C. M., V. L. Prenger, and M. Miller. 1998. Linkage of the apo CIII microsatellite with isolated low high-density lipoprotein cholesterol. Hum. Genet. 102: 273-281.
109. Gagnon, F., G. P. Jarvik, A. G. Motulsky, S. S. Deeb, J. D. Brunzell, and E. M. Wijsman. 2003. Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment. Hum. Genet. 113: 522-533.
110. Pennacchio, L. A., and E. M. Rubin. 2003. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler. Thromb. Vasc. Biol. 23: 529-534.
111. Blatter Garin, M. C., X. Moren, and R. W. James. 2006. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J. Lipid Res. 47: 515-520.
112. van Himbergen, T. M., M. Roest, J. de Graaf, E. H. J. M. Jansen, H. Hattori, J. J. P. Kastelein, H. A. M. Voorbij, A. F. H. Stalenhoef, and L. J. H. van Tits. 2005. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 46: 445-451.
113. Weggemans, R. M., P. L. Zock, E. S. Tai, J. M. Ordovas, H. O. F. Molhuizen, and M. B. Katan. 2002. ATP binding cassette G5 C1950G polymorphism may affect blood cholesterol concentrations in humans. Clin. Genet. 62: 226-229.
114. Acalovschi, M., A. Ciocan, O. Mostean, S. Tirziu, E. Chiorean, H. Keppeler, R. Schirin-Sokhan, and F. Lammert. 2006. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones. Eur. J. Intern. Med. 17: 490-494.
115. Civeira, F., J. Genest, M. Pocovi, D. N. Salem, P. N. Herbert, P. W. Wilson, E. J. Schaefer, and J. M. Ordovas. 1992. The MspI restriction fragment length polymorphism 3′ to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 92: 165-176.
116. Kessling, A. M., J. Rajput-Wiliams, D. Bainton, J. Scott, N. E. Miller, I. Baker, and S. E. Humphries. 1988. DNA polymorphisms of the apolipoprotein AII and AI-CIII-AIV genes: a study in men selected for differences in high-density-lipoprotein cholesterol concentration. Am. J. Hum. Genet. 42: 458-467.
117. Weissglas-Volkov, D., A. Huertas-Vazquez, E. Suviolahti, J. Lee, C. Plaisier, S. Canizales-Quinteros, T. Tusie-Luna, C. Aguilar-Salinas, M. Taskinen, and P. Pajukanta. 2006. Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes. 55: 1970-1977.
118. Lee, J. C, D. Weissglas-Volkov, M. Kyttala, Z. Dastani, R. Cantor, E. Sobel, C. Plaisier, J. Engert, M. van Greevenbroek, J. Kane, et al. 2008. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am. J. Hum. Genet. 83: 180-192.
119. Aqeilan, R. I., and C. Croce. 2007. WWOX in biological control and tumorigenesis. J. Cell. Physiol. 212: 307-310.
120. Aqeilan, R. I., J. P. Hagan, A. de Bruin, M. Rawahneh, Z. Salah, E. Gaudio, H. Siddiqui, S. Volinia, H. Alder, J. B. Lian, et al. 2009. Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology. 150: 1530-1535.
121. Aqeilan, R. I., F. Trapasso, S. Hussain, S. Costinean, D. Marshall, Y. Pekarsky, J. Hagan, N. Zanesi, M. Kaou, G. Stein, et al. 2007. Targeted deletion of Wwox reveals a tumor suppressor function. Proc. Natl. Acad. Sci. USA. 104: 3949-3954.
122. Willer, C. J., S. Sanna, A. Jackson, A. Scuteri, L. Bonnycastle, R. Clarke, S. Heath, N. Timpson, S. Najjar, H. Stringham, et al. 2008. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40: 161-169.
123. Kathiresan, S., C. Willer, G. Peloso, S. Demissie, K. Musunuru, E. Schadt, L. Kaplan, D. Bennett, Y. Li, T. Tanaka, et al. 2009. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41: 56-65.
124. Cohen, J. C., R. S. Kiss, A. Pertsemlidis, Y. L. Marcel, R. McPherson, and H. H. Hobbs. 2004. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 305: 869-872.
125. Frikke-Schmidt, R., B. Nordestgaard, G. Jensen, and A. Tybjaerg-Hansen. 2004. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114: 1343-1353.
126. Masson, D., X. Jiang, L. Lagrost, and A. R. Tall. 2009. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J. Lipid Res. 50: S201-S206.
127. Aouizerat, B. E., M. B. Engler, Y. Natanzon, M. Kulkarni, J. Song, C. Eng, J. Huuskonen, C. Rivera, A. Poon, M. Bensley, et al. 2006. Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia. J. Lipid Res. 47: 787-793.
128. Engler, M. B., C. R. Pullinger, M. J. Malloy, Y. Natanzon, M. V. Kulkarni, J. Song, C. Eng, J. Huuskonen, C. Rivera, A. Poon, et al. 2008. Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia. Metabolism. 57: 1719-1724.
129. Ishida, T., S. Choi, R. K. Kundu, K. Hirata, E. M. Rubin, A. D. Cooper, and T. Quertermous. 2003. Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 111: 347-355.
130. Edmondson, A. C., R. J. Brown, S. Kathiresan, L. A. Cupples, S. Demissie, A. K. Manning, M. K. Jensen, E. B. Rimm, J. Wang, A. Rodrigues, et al. 2009. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J. Clin. Invest. 119: 1042-1050.
131. Sukonina, V., A. Lookene, T. Olivecrona, and G. Olivecrona. 2006. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA. 103: 17450-17455.
132. Köster, A., Y. B. Chao, M. Mosior, A. Ford, P. A. Gonzalez-DeWhitt, J. E. Hale, D. Li, Y. Qiu, C. C. Fraser, D. D. Yang, et al. 2005. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 146: 4943-4950.
133. Romeo, S., L. Pennacchio, Y. Fu, E. Boerwinkle, A. Tybjaerg-Hansen, H. Hobbs, and J. Cohen. 2007. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39: 513-516.
134. Kort, E. N., D. G. Ballinger, W. Ding, S. C. Hunt, B. R. Bowen, V. Abkevich, K. Bulka, B. Campbell, C. Capener, A. Gutin, et al. 2000. Evidence of linkage of familial hypoalphalipoproteinemia to a novel locus on chromosome 11q23. Am. J. Hum. Genet. 66: 1845-1856.
135. International Human Genome Sequencing Consortium. 2004. Finishing the euchromatic sequence of the human genome. Nature. 431: 931-945.
136. Steemers, F. J., W. Chang, G. Lee, D. Barker, R. Shen, and K. Gunderson. 2006. Whole-genome genotyping with the single-base extension assay. Nat. Methods. 3: 31-33.
137. Kathiresan, S., K. Musunuru, and M. Orho-Melander. 2008. Defining the spectrum of alleles that contribute to blood lipid concentrations in humans. Curr. Opin. Lipidol. 19: 122-127.
138. Hindorff, L. A., P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta, F. S. Collins, and T. A. Manolio. 2009. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA. 106: 9362-9367.
139. Frazer, K. A., D. G. Ballinger, D. R. Cox, D. A. Hinds, L. L. Stuve, R. A. Gibbs, J. W. Belmont, A. Boudreau, P. Hardenbol, S. M. Leal, et al. 2007. A second generation human haplotype map of over 3.1 million SNPs. Nature. 449: 851-861.
140. Altshuler, D., M. J. Daly, and E. S. Lander. 2008. Genetic mapping in human disease. Science. 322: 881-888.
141. Pe'er, I., R. Yelensky, D. Altshuler, and M. Daly. 2008. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 32: 381-385.
142. Skol, A. D., L. Scott, G. Abecasis, and M. Boehnke. 2007. Optimal designs for two-stage genome-wide association studies. Genet. Epidemiol. 31: 776-788.
143. Cantor, R. M., K. Lange, and J. S. Sinsheimer. 2010. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 86: 6-22.
144. Kathiresan, S., O. Melander, C. Guiducci, A. Surti, N. Burtt, M. Rieder, G. Cooper, C. Roos, B. Voight, A. Havulinna, et al. 2008. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40: 189-197.
145. Servin, B., and M. Stephens. 2007. Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet. 3: e114.
146. Marchini, J., B. Howie, S. Myers, G. McVean, and P. Donnelly. 2007. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39: 906-913.
147. Kathiresan, S., A. K. Manning, S. Demissie, R. B. D'Agostino, A. Surti,
148. Aulchenko, Y. S., S. Ripatti, I. Lindqvist, D. Boomsma, I. Heid, P. Pramstaller, B. Penninx, A. Janssens, J. Wilson, T. Spector, et al. 2009. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41: 47-55.
149. Sabatti, C., S. K. Service, A. Hartikainen, A. Pouta, S. Ripatti, J. Brodsky, C. G. Jones, N. A. Zaitlen, T. Varilo, M. Kaakinen, et al. 2009. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat. Genet. 41: 35-46.
150. Heid, I. M., E. Boes, M. Muller, B. Kollerits, C. Lamina, S. Coassin, C. Gieger, A. Doring, N. Klopp, R. Frikke-Schmidt, et al. 2008. Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. Circ Cardiovasc Genet. 1: 10-20.
151. Wallace, C., S. J. Newhouse, P. Braund, F. Zhang, M. Tobin, M. Falchi, K. Ahmadi, R. J. Dobson, A. C. B. Marçano, C. Hajat, et al. 2008. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82: 139-149.
152. Kooner, J. S., J. Chambers, C. Aguilar-Salinas, D. Hinds, C. Hyde, G. Warnes, F. Gomez Perez, K. Frazer, P. Elliott, J. Scott, et al. 2008. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 40: 149-151.
153. Chasman, D. I., G. Pare, R. Y. Zee, A. N. Parker, N. R. Cook, J. E. Buring, D. J. Kwiatkowski, L. M. Rose, J. D. Smith, P. T. Williams, et al. 2008. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet. 1: 21-30.
154. Ridker, P. M., G. Paré, A. N. Parker, R. Y. L. Zee, J. P. Miletich, and D. I. Chasman. 2009. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2: 26-33.
155. Hegele, R. A. 2009. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10: 109-121.
156. Baylin, A., E. Ruiz-Narvaez, P. Kraft, and H. Campos. 2007. alpha-Linolenic acid, Delta6-desaturase gene polymorphism, and the risk of nonfatal myocardial infarction. Am. J. Clin. Nutr. 85: 554-560.
157. Hayhurst, G. P., Y. H. Lee, G. Lambert, J. M. Ward, and F. J. Gonzalez. 2001. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403.
158. Murphy, C., A. M. Murray, S. Meaney, and M. Gåfvels. 2007. Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism. Biochem. Biophys. Res. Commun. 355: 359-364.
159. Dobson, C. M., T. Wai, D. Leclerc, H. Kadir, M. Narang, J. P. Lerner-Ellis, T. J. Hudson, D. S. Rosenblatt, and R. A. Gravel. 2002. Identification of the gene responsible for the cblB complementation group of vitamin B12-dependent methylmalonic aciduria. Hum. Mol. Genet. 11: 3361-3369.
160. Zelcer, N., and P. Tontonoz. 2006. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607-614.
161. Wandall, H. H., H. Hassan, E. Mirgorodskaya, A. K. Kristensen, P. Roepstorff, E. P. Bennett, P. A. Nielsen, M. A. Hollingsworth, J. Burchell, J. Taylor-Papadimitriou, et al. 1997. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N- acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J. Biol. Chem. 272: 23503-23514.
162. Lichtenstein, L., J. F. P. Berbée, S. J. van Dijk, K. W. van Dijk, A. Bensadoun, I. P. Kema, P. J. Voshol, M. Müller, P. C. N. Rensen, and S. Kersten. 2007. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler. Thromb. Vasc. Biol. 27: 2420-2427.
163. Yoon, J. C., T. W. Chickering, E. D. Rosen, B. Dussault, Y. Qin, A. Soukas, J. M. Friedman, W. E. Holmes, and B. M. Spiegelman. 2000. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20: 5343-5349.
164. Schaeffer, L., H. Gohlke, M. Müller, I. M. Heid, L. J. Palmer, I. Kompauer, H. Demmelmair, T. Illig, B. Koletzko, and J. Heinrich. 2006. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet. 15: 1745-1756.
165. Tanaka, T., J. Shen, G. R. Abecasis, A. Kisialiou, J. M. Ordovas, J. M. Guralnik, A. Singleton, S. Bandinelli, A. Cherubini, D. Arnett, et al. 2009. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet. 5: e1000338.
166. Calabresi, L., B. Villa, M. Canavesi, C. R. Sirtori, R. W. James, F. Bernini, and G. Franceschini. 2004. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 53: 153-158.
167. Harris, W. S. 1989. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid Res. 30: 785-807.
168. Connor, W. E., C. A. DeFrancesco, and S. L. Connor. 1993. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann. N. Y. Acad. Sci. 683: 16-34.
169. Dagnelie, P. C., J. D. Bell, S. C. Williams, T. E. Bates, P. D. Abel, and C. S. Foster. 1994. Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors. Lipids. 29: 195-203.
170. Yamagata, K., H. Furuta, N. Oda, P. Kaisaki, S. Menzel, N. Cox, S. Fajans, S. Signorini, M. Stoffel, and G. Bell. 1996. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature. 384: 458-460. (Pubitemid 26414661)
171. Pearson, E. R., S. Pruhova, C. J. Tack, A. Johansen, H. A. J. Castleden, P. J. Lumb, A. S. Wierzbicki, P. M. Clark, J. Lebl, O. Pedersen, et al. 2005. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 48: 878-885.
172. Yamagata, K., N. Oda, P. J. Kaisaki, S. Menzel, H. Furuta, M. Vaxillaire, L. Southam, R. D. Cox, G. M. Lathrop, V. V. Boriraj, et al. 1996. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 384: 455-458.
173. Zhu, Q., K. Yamagata, A. Miura, N. Shihara, Y. Horikawa, J. Takeda, J. Miyagawa, and Y. Matsuzawa. 2003. T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects. Diabetologia. 46: 567-573.
174. Holleboom, A. G., M. Vergeer, G. K. Hovingh, J. J. Kastelein, and J. A. Kuivenhoven. 2008. The value of HDL genetics. Curr. Opin. Lipidol. 19: 385-394.
175. Vaith, P., G. Assmann, and G. Uhlenbruck. 1978. Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins. Biochim. Biophys. Acta. 541: 234-240.
176. Magrané, J., R. P. Casaroli-Marano, M. Reina, M. Gåfvels, and S. Vilaró. 1999. The role of O-linked sugars in determining the very low density lipoprotein receptor stability or release from the cell. FEBS Lett. 451: 56-62.
177. Schindler, P. A., C. A. Settineri, X. Collet, C. J. Fielding, and A. L. Burlingame. 1995. Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. Protein Sci. 4: 791-803.
178. Edmondson, A., A. Khera, S. Khetarpal, S. Kathiresan, and D. Rader. Functional characterization of GALNT2, a novel GWAS locus associated with HDL-C. Abstract 250, American Society of Human Genetics 59th Annual Meeting, Honolulu Hawaii, 2009.
179. Haas, D., and G. F. Hoffmann. 2006. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J. Rare Dis. 1: 13.
180. Klasen, I. S., J. H. Göertz, G. A. van de Wiel, C. M. Weemaes, J. W. van der Meer, and J. P. Drenth. 2001. Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome. Clin. Diagn. Lab. Immunol. 8: 58-61.
181. Tontonoz, P., and D. J. Mangelsdorf. 2003. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17: 985-993.
182. Blatch, G. L., and M. Lässle. 1999. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. Bioessays. 21: 932-939.
183. Kathiresan, S., O. Melander, D. Anevski, C. Guiducci, N. P. Burtt, C. Roos, J. N. Hirschhorn, G. Berglund, B. Hedblad, L. Groop, et al. 2008. Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358: 1240-1249.
184. Goldstein, D. B. 2009. Common genetic variation and human traits. N. Engl. J. Med. 360: 1696-1698.
185. Purcell, S. M., N. R. Wray, J. L. Stone, P. M. Visscher, M. C. O'Donovan, P. F. Sullivan, and P. Sklar. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 460: 748-752.
186. Kuehn, B. M. 2008. 1000 Genomes Project promises closer look at variation in human genome. JAMA. 300: 2715.
187. Manolio, T. 2009. Cohort studies and the genetics of complex disease. Nat. Genet. 41: 5-6.
188. Villarreal-Molina, M. T., C. A. Aguilar-Salinas, M. Rodríguez- Cruz, D. Riaño, M. Villalobos-Comparan, R. Coral-Vazquez, M. Menjivar, P. Yescas-Gomez, M. Königsoerg-Fainstein, S. Romero-Hidalgo, et al. 2007. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes. 56: 1881-1887.
189. Ioannidis, J. P. 2009. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet. 2: 7-15.
190. Keebler, M. E., C. L. Sanders, A. Surti, C. Guiducci, N. P. Burtt, and S. Kathiresan. 2009. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the Multiethnic United States National Health and Nutrition Examination Survey III. Circ Cardiovasc Genet. 2: 238-243.
191. Nakayama, K., T. Bayasgalan, K. Yamanaka, M. Kumada, T. Gotoh, N. Utsumi, Y. Yanagisawa, M. Okayama, E. Kajii, S. Ishibashi, et al. 2009. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J. Med. Genet. 46: 370-374.
192. Weissglas-Volkov, D., C. A. Aguilar-Salinas, J. S. Sinsheimer, L. Riba, A. Huertas-Vazquez, M. L. Ordoñez-Sánchez, R. Rodriguez-Guillen, R. M. Cantor, T. Tusie-Luna, and P. Pajukanta. 2010. Investigation of variants identified in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in mexican dyslipidemic study samples. Circ Cardiovasc Genet. 3: 31-38.
193. Aguilar-Salinas, C., S. Canizales-Quinteros, R. Rojas-Martinez, R. Mehta, M. Villarreal-Molina, O. Arellano-Campos, L. Riba, F. Gomez-Perez, and M. Tusie-Luna. 2009. Hypoalphalipoproteinemia in populations of Native American ancestry: an opportunity to assess the interaction of genes and the environment. Curr. Opin. Lipidol. 20: 92-97.
194. Kuller, L. H. 2004. Ethnic differences in atherosclerosis, cardiovascular disease and lipid metabolism. Curr. Opin. Lipidol. 15: 109-113.
195. Iafrate, A. J., L. Feuk, M. Rivera, M. Listewnik, P. Donahoe, Y. Qi, S. Scherer, and C. Lee. 2004. Detection of large-scale variation in the human genome. Nat. Genet. 36: 949-951.
196. Sebat, J., B. Lakshmi, J. Troge, J. Alexander, J. Young, P. Lundin, S. Maner, H. Massa, M. Walker, M. Chi, et al. 2004. Large-scale copy number polymorphism in the human genome. Science. 305: 525-528.
197. Lanktree, M., and R. A. Hegele. 2008. Copy number variation in metabolic phenotypes. Cytogenet. Genome Res. 123: 169-175.
198. Karathanasis, S. K., E. Ferris, and I. A. Haddad. 1987. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc. Natl. Acad. Sci. USA. 84: 7198-7202.
199. Ordovas, J. M., D. K. Cassidy, F. Civeira, C. L. Bisgaier, and E. J. Schaefer. 1989. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J. Biol. Chem. 264: 16339-16342.
200. Pollex, R. L., and R. A. Hegele. 2007. Genomic copy number variation and its potential role in lipoprotein and metabolic phenotypes . Curr. Opin. Lipidol. 18: 174-180.
201. McCarroll, S. A., and D. M. Altshuler. 2007. Copy-number variation and association studies of human disease. Nat. Genet. 39: S37-S42.
202. McCarroll, S. A., F. Kuruvilla, J. Korn, S. Cawley, J. Nemesh, A. Wysoker, M. Shapero, P. de Bakker, J. Maller, A. Kirby, et al. 2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat. Genet. 40: 1166-1174.
203. Kathiresan, S., B. Voight, S. Purcell, K. Musunuru, D. Ardissino, P. Mannucci, S. Anand, J. Engert, N. Samani, H. Schunkert, et al. 2009. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41: 334-341.
204. Tucker, T., M. Marra, and J. M. Friedman. 2009. Massively parallel sequencing: the next big thing in genetic medicine. Am. J. Hum. Genet. 85: 142-154.
205. Mardis, E. R. 2008. The impact of next-generation sequencing technology on genetics. Trends Genet. 24: 133-141.
206. Yeager, M., N. Xiao, R. B. Hayes, P. Bouffard, B. Desany, L. Burdett, N. Orr, C. Matthews, L. Qi, A. Crenshaw, et al. 2008. Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum. Genet. 124: 161-170.
207. Ng, S. B., K. J. Buckingham, C. Lee, A. W. Bigham, H. K. Tabor, K. M. Dent, C. D. Huff, P. T. Shannon, E. W. Jabs, D. A. Nickerson, et al. 2010. Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42: 30-35.
208. Albert, T., M. Molla, D. Muzny, L. Nazareth, D. Wheeler, X. Song, T. Richmond, C. Middle, M. Rodesch, C. Packard, et al. 2007. Direct selection of human genomic loci by microarray hybridization. Nat. Methods. 4: 903-905.
209. Hodges, E., Z. Xuan, V. Balija, M. Kramer, M. Molla, S. Smith, C. Middle, M. Rodesch, T. Albert, G. Hannon, et al. 2007. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 39: 1522-1527.
210. Birney, E., J. Stamatoyannopoulos, A. Dutta, R. Guigo, T. Gingeras, E. Margulies, Z. Weng, M. Snyder, E. Dermitzakis, R. Thurman, et al. 2007. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447: 799-816.
211. Cookson, W., L. Liang, G. Abecasis, M. Moffatt, and M. Lathrop. 2009. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 10: 184-194.
212. Li, B., and S. M. Leal. 2008. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83: 311-321.
213. Ng, P. C., S. Levy, J. Huang, T. B. Stockwell, B. P. Walenz, K. Li, N. Axelrod, D. A. Busam, R. L. Strausberg, and J. C. Venter. 2008. Genetic variation in an individual human exome. PLoS Genet. 4: e1000160.
214. Roach, J. C., G. Glusman, A. F. A. Smit, C. D. Huff, R. Hubley, P. T. Shannon, L. Rowen, K. P. Pant, N. Goodman, M. Bamshad, et al. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. 328: 636-639.
215. Wittrup, H. H., R. V. Andersen, A. Tybjaerg-Hansen, G. B. Jensen, and B. G. Nordestgaard. 2006. Combined analysis of six lipoprotein lipase genetic variants on triglycerides, high-density lipoprotein, and ischemic heart disease: cross-sectional, prospective, and case-control studies from the Copenhagen City Heart Study. J. Clin. Endocrinol. Metab. 91: 1438-1445.
216. Junyent, M., K. L. Tucker, C. E. Smith, J. M. Lane, J. Mattei, C. Q. Lai, L. D. Parnell, and J. M. Ordovas. 2009. The effects of ABCG5/G8 polymorphisms on HDL-cholesterol concentrations depend on ABCA1 genetic variants in the Boston Puerto Rican Health Study. Nutr Metab Cardiovasc Dis. Epub ahead of print. August 17, 2009.
217. Sorlí, J. V., D. Corella, F. Francés, J. B. Ramírez, J. I. González, M. Guillén, and O. Portolés. 2006. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin. Chim. Acta. 366: 196-203.
218. Heidema, A. G., J. M. A. Boer, N. Nagelkerke, E. C. M. Mariman, D. L. van der A, and E. J. M. Feskens. 2006. The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet. 7: 23.
219. Lehár, J., A. Krueger, G. Zimmermann, and A. Borisy. 2008. High-order combination effects and biological robustness. Mol. Syst. Biol. 4: 215.
220. Segrè, D., A. Deluna, G. M. Church, and R. Kishony. 2005. Modular epistasis in yeast metabolism. Nat. Genet. 37: 77-83.
221. Smith, C. E., D. K. Arnett, M. Y. Tsai, C. Lai, L. D. Parnell, J. Shen, M. Laclaustra, M. Junyent, and J. M. Ordovás. 2009. Physical inactivity interacts with an endothelial lipase polymorphism to modulate high density lipoprotein cholesterol in the GOLDN study. Atherosclerosis. 206: 500-504.
222. Grarup, N., C. H. Andreasen, M. K. Andersen, A. Albrechtsen, A. Sandbaek, T. Lauritzen, K. Borch-Johnsen, T. Jørgensen, O. Schmitz, T. Hansen, et al. 2008. The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects. J. Clin. Endocrinol. Metab. 93: 2294-2299.
223. Ordovas, J. M., D. Corella, S. Demissie, L. A. Cupples, P. Couture, O. Coltell, P. W. F. Wilson, E. J. Schaefer, and K. L. Tucker. 2002. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation. 106: 2315-2321.
224. Nettleton, J. A., L. M. Steffen, C. M. Ballantyne, E. Boerwinkle, and A. R. Folsom. 2007. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis. 194: e131-e140.
225. Junyent, M., L. D. Parnell, C. Lai, Y. Lee, C. E. Smith, D. K. Arnett, M. Y. Tsai, E. K. Kabagambe, R. J. Straka, M. Province, et al. 2009. Novel variants at KCTD10, MVK, and MMAB genes interact with dietary carbohydrates to modulate HDL-cholesterol concentrations in the Genetics of Lipid Lowering Drugs and Diet Network Study. Am. J. Clin. Nutr. 90: 686-694.
226. Jensen, M. K., K. J. Mukamal, K. Overvad, and E. B. Rimm. 2008. Alcohol consumption, TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women. Eur. Heart J. 29: 104-112.
227. Mosher, M. J., L. J. Martin, L. A. Cupples, Q. Yang, T. D. Dyer, J. T. Williams, and K. E. North. 2005. Genotype-by-sex interaction in the regulation of high-density lipoprotein: the Framingham Heart Study. Hum. Biol. 77: 773-793.
228. Mosher, M. J., L. A. Lange, B. V. Howard, E. T. Lee, L. G. Best, R. R. Fabsitz, J. W. Maccluer, and K. E. North. 2008. Sex-specific interaction between APOE genotype and carbohydrate intake affects plasma HDL-C levels: the Strong Heart Family Study. Genes Nutr. 3: 87-97.
229. Chasman, D. I., G. Paré, S. Mora, J. C. Hopewell, G. Peloso, R. Clarke, L. A. Cupples, A. Hamsten, S. Kathiresan, A. Mälarstig, et al. 2009. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5: e1000730.
230. Carlquist, J., and J. L. Anderson. 2007. Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis. Curr. Opin. Cardiol. 22: 352-358.
231. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, and A. M. Fogelman. 2006. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat. Clin. Pract. Endocrinol. Metab. 2: 504-511.
232. Delgado-Lista, J., F. Perez-Jimenez, J. Ruano, P. Perez-Martinez, F. Fuentes, J. Criado-Garcia, L. D. Parnell, A. Garcia-Rios, J. M. Ordovas, and J. Lopez-Miranda. 2009. Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men. J. Lipid Res. 51: 63-73.
233. Rea, T. J., C. M. Brown, and C. F. Sing. 2006. Complex adaptive system models and the genetic analysis of plasma HDL-cholesterol concentration. Perspect. Biol. Med. 49: 490-503.
234. Lusis, A. J. 2006. A thematic review series: systems biology approaches to metabolic and cardiovascular disorders. J. Lipid Res. 47: 1887-1890.
235. Schadt, E. E., C. Molony, E. Chudin, K. Hao, X. Yang, P. Y. Lum, A. Kasarskis, B. Zhang, S. Wang, C. Suver, et al. 2008. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6: e107.
236. Göring, H. H. H., J. E. Curran, M. P. Johnson, T. D. Dyer, J. Charlesworth, S. A. Cole, J. B. M. Jowett, L. J. Abraham, D. L. Rainwater, A. G. Comuzzie, et al. 2007. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat. Genet. 39: 1208-1216.
237. Mootha, V. K., C. M. Lindgren, K. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34: 267-273.
238. Lusis, A., A. Attie, and K. Reue. 2008. Metabolic syndrome: from epidemiology to systems biology. Nat. Rev. Genet. 9: 819-830.
239. Emilsson, V., G. Thorleifsson, B. Zhang, A. S. Leonardson, F. Zink, J. Zhu, S. Carlson, A. Helgason, G. B. Walters, S. Gunnarsdottir, et al. 2008. Genetics of gene expression and its effect on disease. Nature. 452: 423-428.
240. Plaisier, C. L., S. Horvath, A. Huertas-Vazquez, I. Cruz-Bautista, M. F. Herrera, T. Tusie-Luna, C. Aguilar-Salinas, and P. Pajukanta. 2009. A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. PLoS Genet. 5: e1000642.